Glenmark Pharma, USA continues to expand its OTC portfolio with acquisition of approved ANDAs from Wockhardt 

Glenmark Pharma has announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc, USA
(Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole Delayed Release Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 per cent (OTC) in the US from Wockhardt.

Sanjeev Krishan, President, Glenmark Pharma, US, commented, “The Over-The-Counter market
has long been an important segment of Glenmark’s portfolio around the world. Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the United States and our commitment to ensuring patients have access to high-quality, affordable medicines.”

Glenmark’s current portfolio consists of 175 products authorised for distribution in the US marketplace and 48 ANDAs pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.